Determination of mycophenolic acid in human plasma by ultra performance liquid chromatography tandem mass spectrometry

Upadhyay, Vinod; Trivedi, Vikas; Shah, Gaurang; Yadav, Manish; Shrivastav, Pranav S.

doi:10.1016/j.jpha.2013.06.001

Cited by 16 publications

(14 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several assays have been reported for the analysis of MPA and its metabolites by LC-MS/MS in different matrices (Benech et al, 2007;Brandhorst et al, 2006;Delavenne et al, 2011;Heinig et al, 2010;Kawanishi et al, 2015;Klepacki et al, 2012;Kuhn et al, 2009;Laverdiere et al, 2012;Md Dom et al, 2014;Shen et al, 2009;Upadhyay et al, 2014;Wiesen et al, 2012). However, relatively few assays are available for simultaneous quantification of MPA and its glucuronide metabolites with sufficient sensitivity for AcMPAG, which has a relatively low abundance in comparison with MPAG.…”

Section: Introductionmentioning

confidence: 99%

Simultaneous quantification of mycophenolic acid and its glucuronide metabolites in human plasma by an UPLC–MS/MS assay

Zhang

Chow

Renbarger

2016

Biomedical Chromatography

View full text Add to dashboard Cite

The aim of this study was to develop a reliable UPLC-MS/MS assay for accurate quantification of mycophenolic acid (MPA) and its glucuronide conjugates in human plasma. Plasma proteins were precipitated with acetonitrile and the chromatographic separation was achieved on a C18 column with a gradient elution. The detection was performed by a triple quadrupole mass spectrometer in the positive electrospray ionization and multiple reaction monitoring mode. Linearity of the assay was demonstrated over the range of 20-10,000 ng/mL for MPA and MPA glucuronide (MPAG), and 2-1000 ng/mL for acyl MPA glucuronide in human plasma. The assay was precise and accurate with coefficient of variation and bias <15%. MPA and MPAG were stable at 25 °C up to 1 day in both heparin- and EDTA-treated blood. In heparin- and EDTA-plasma, MPA and MPAG were stable for at least 1 week at 25 and 4 °C, and 1 month at -20 °C. However, 99% acyl MPA glucuronide degraded in both heparin- and EDTA-blood as well as plasma when stored at room temperature for 1 day. All the analytes remained stable for at least 3 months in acidified EDTA-plasma at -80 °C. The assay was successfully applied on patients post hematopoietic stem cell transplantation. Copyright © 2016 John Wiley & Sons, Ltd.

show abstract

Section: Introductionmentioning

confidence: 99%

Simultaneous quantification of mycophenolic acid and its glucuronide metabolites in human plasma by an UPLC–MS/MS assay

Zhang

Chow

Renbarger

2016

Biomedical Chromatography

View full text Add to dashboard Cite

show abstract

“…4.0. The tentative identification of phenolics was carried out considering their UV and mass spectra, as well as by comparison of their retention time and fragmentation pattern with those of authentic standards when available and/or literature data (Braña et al ; Upadhyay et al ; Álvarez‐Álvarez et al ).…”

Section: Methodsmentioning

confidence: 99%

Unique secondary metabolites of a Streptomyces strain isolated from extreme salty wetland show antioxidant and antibacterial activities

Riahi

Hosni²,

Raïes

et al. 2019

J Appl Microbiol

View full text Add to dashboard Cite

Aims To identify and assess the biological activities of the crude extract of a Streptomyces isolate from a salty wetland, an extreme environment likely to induce secondary metabolism of micro‐organisms. Methods and Results The crude extract from the isolate Streptomyces lanatus strain AR2 displayed antibacterial activity against Gram‐positive bacteria (MICs ranging from 5 to 50 μg ml−1) and antioxidant activity as revealed in DPPH (2,2‐diphenyl‐1‐picrylhydrazyl) assay (IC50 of 0·74 mg ml−1), ferric reducing antioxidant power (IC50 of 1·12 mg ml−1) and metal‐chelating power (IC50 of 1·84 mg ml−1) assays. Accordingly, the extract attenuated the H2O2‐induced oxidative stress in the eukaryotic cell model Saccharomyces cerevisiae, assessed by flow cytometry. The profiling of secondary metabolites by HPLC‐PDA‐ESI‐MS/MS revealed the presence of 17 compounds, some of which reported in Streptomyces for the first time to the best of our knowledge: genistein‐7‐O‐glucuronide, naringenin‐7‐O‐rutinoside and resveratrol. Conclusions Streptomyces lanatus AR2 produced unique polyketides and phenolic compounds with noticeable bioactivities, allowing adaptation to the extreme environment. Significance and Impact of the Study Sabkhat Seijoumi salty wetland represents a potential niche for Streptomyces yielding useful natural products for biotechnological, pharmaceutical and medical applications.

show abstract

“…The advantage of UPLC over other chromatographic methods such as HPLC is its ability to increase the analysis speed without reducing the method efficiency. Besides, improved separation efficiency and a decrease in the analysis time can be achieved by reducing the particle size of the column packing material (Upadhyay, Trivedi, Shah, Yadav, & Shrivastav, ).…”

Section: Introductionmentioning

confidence: 99%

“…Several UPLC–MS/MS methods that quantify MPA in plasma have been reported (Buchwald et al, ; Delavenne, Juthier, Pons, Mariat, & Basset, ; Maddela et al, ; Upadhyay et al, ). However, most of these methods use deuterated MPA (MPA‐D3) as labeled internal standard (IS) which is an expensive reagent (1 mg is about US$ 283; LGC Standards/Analytical Reference Materials International, Manchester, NH, USA).…”

Section: Introductionmentioning

confidence: 99%

Determination of mycophenolic acid in human plasma by ultra‐performance liquid chromatography–tandem mass spectrometry and its pharmacokinetic application in kidney transplant patients

Reséndiz-Galván

Romano‐Aguilar

Medellín‐Garibay

et al. 2019

Biomedical Chromatography

View full text Add to dashboard Cite

To implement and validate an analytical method by ultra-performance liquid chromatography-tandem mass spectrometry (UPLC MS/MS) to quantify mycophenolic acid (MPA) in kidney transplant patients. Quantification of MPA was performed in an ACQUITY UPLC H Class system coupled to a Xevo TQD detector and it was extracted from plasma samples by protein precipitation. The chromatographic separation was achieved through an ACQUITY HSS C 18 SB column with 0.1% formic acid and acetonitrile (60:40 vol/vol) as mobile phase. The pharmacokinetic parameters were calculated by non-compartmental analysis of MPA plasma concentrations from 10 kidney transplant patients. The linear range for MPA quantification was 0.2-30 mg/L with a limit of detection of 0.07 mg/L; the mean extraction recovery was 99.99%. The mean intra-and inter-day variability were 2.98% and 3.4% with a percentage of deviation of 8.4% and 6.6%, respectively. Mean maximal concentration of 10 mg/L at 1.5 h, area under the concentrationtime curve of 36.8 mg·h/L, elimination half-life of 3.9 h, clearance of 0.32 L/h/kg and volume of distribution of 1.65 L/kg were obtained from MPA pharmacokinetics profiles. A simple, fast and reliable UPLC-MS/MS method to quantify MPA in plasma was validated and has been applied for pharmacokinetic analysis in kidney transplant patients.

show abstract

Determination of mycophenolic acid in human plasma by ultra performance liquid chromatography tandem mass spectrometry

Cited by 16 publications

References 47 publications

Simultaneous quantification of mycophenolic acid and its glucuronide metabolites in human plasma by an UPLC–MS/MS assay

Simultaneous quantification of mycophenolic acid and its glucuronide metabolites in human plasma by an UPLC–MS/MS assay

Unique secondary metabolites of a Streptomyces strain isolated from extreme salty wetland show antioxidant and antibacterial activities

Determination of mycophenolic acid in human plasma by ultra‐performance liquid chromatography–tandem mass spectrometry and its pharmacokinetic application in kidney transplant patients

Contact Info

Product

Resources

About